Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Woluwe-Saint-Lambert
Clinical trial register · Belgium

Clinical Trials in Woluwe-Saint-Lambert, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Belgium and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3055 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:19 UTC
3055
Studies in scope
all four open statuses
1723
Recruiting now
open to new participants
505
Lead sponsors
across recruiting studies
Top sites
Leuven 1275 Brussels 1118 Ghent 1030 Liège 562 Edegem 441
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Incyte Corporation7 AbbVie4 Université Catholique de Louvain3 argenx2 Zimmer Biomet2 Vertex Pharmaceuticals Incorporated2 Cliniques universitaires Saint-Luc- Université Catholique de Louvain2 Olema Pharmaceuticals, Inc.2 Eli Lilly and Company2 Novartis Pharmaceuticals2 Janssen Research & Development, LLC2 BioNTech SE2 SynOx Therapeutics Limited1 MedSIR1 Bayer1 Alexion Pharmaceuticals, Inc.1 Philipp Dutkowski1 Corbus Pharmaceuticals Inc.1 Daiichi Sankyo1 Sanofi1 Population Health Research Institute1 Solstice Oncology, Inc.1 Stemline Therapeutics, Inc.1 Drahomir Aujesky1 Bristol-Myers Squibb1 Show all 37
Site location
Leuven1275 Brussels1118 Ghent1030 Liège562 Edegem441 Antwerp290 Bruges263 Roeselare249 Hasselt215 Aalst185 Kortrijk183 Charleroi175 Genk174 Anderlecht167 Yvoir153 Namur138 Jette128 Sint-Niklaas116 Bonheiden101 Wilrijk75 Brasschaat72 Mechelen61 La Louvière59 Woluwe-Saint-Lambert57 Ottignies48 Show all 205
All 205 locations
Target enrolment
to

Trials with a site in Woluwe-Saint-Lambert

57 of 3055 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Belgium
Start
Recruiting
Solstice Oncology, Inc.
Phase 2
100
Anderlecht, Bonheiden, Ghent, Leuven, Liège, Ostend, Woluwe-Saint-Lambert
2026-09-30
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
Edegem, Ghent, Leuven, Sint-Niklaas, Woluwe-Saint-Lambert
2026-09-29
Recruiting
Incyte Corporation
Phase 3
426
Anderlecht, Brussels, Leuven, Liège, Roeselare, Woluwe-Saint-Lambert
2026-09-08
Recruiting
Université Catholique de Louvain
Not applicable
225
Woluwe-Saint-Lambert
2026-09
Recruiting
Prilenia
Phase 3
400
Anderlecht, Woluwe-Saint-Lambert
2026-07-01
Recruiting
Jules Bordet Institute
Not applicable
31
Anderlecht, Brussels, Woluwe-Saint-Lambert
2026-06-03
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Woluwe-Saint-Lambert, Roeselare
2026-05-27
Recruiting
Incyte Corporation
Phase 2
60
Brussels, Woluwe-Saint-Lambert
2026-05-20
Recruiting
Ipsen
Phase 3
350
Brussels, Woluwe-Saint-Lambert, Edegem, Ghent, Leuven
2026-05-14
Active, closed
Factors Determining the Rate of Adoption of Pharmaceutical Recommendations by Patients in Primary Care Following a Medication Review by a Pharmacist
NCT07606716Polypharmacy (People Under Treatment With 5 or More Drugs), Polypharmacy, Decision-making, Medication Review
Université Catholique de Louvain
Not applicable
123
Woluwe-Saint-Lambert
2026-01-12
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Edegem, Haine-Saint-Paul, Leuven, Sint-Niklaas, Woluwe-Saint-Lambert
2025-12-03
Recruiting
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Not applicable
20
Woluwe-Saint-Lambert
2025-11-18
Recruiting
Incyte Corporation
Phase 3
250
Brussels, Ghent, Leuven, Woluwe-Saint-Lambert
2025-11-13
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Brussels, Woluwe-Saint-Lambert, Kortrijk, Liège, Charleroi
2025-11-03
Recruiting
BioNTech SE
Phase 3
558
Bonheiden, Brussels, Gilly, Leuven, Woluwe-Saint-Lambert
2025-10-30
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Woluwe-Saint-Lambert, Maldegem, Ghent
2025-09-22
Recruiting
HOPE Against Cancer Recurrence in HCC
NCT06717919Liver Transplantation, HCC, Oncological Outcomes
Philipp Dutkowski
Phase 4
220
Leuven, Woluwe-Saint-Lambert
2025-08-01
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Brussels, Edegem, Leuven, Woluwe-Saint-Lambert
2025-07-21
Recruiting
MedSIR
Phase 2
200
Brasschaat, Ghent, Mons, Woluwe-Saint-Lambert
2025-06-30
Active, closed
Incyte Corporation
Phase 3
9
Bruges, Godinne-mont, Leuven, Liège, Roeselare, Woluwe-Saint-Lambert
2025-06-04
Recruiting
Daiichi Sankyo
Phase 3
582
Ghent, Leuven, Liège, Namur, Woluwe-Saint-Lambert
2025-03-19
Recruiting
Bayer
Phase 1
36
Edegem, Woluwe-Saint-Lambert, Ottignies, Liège
2025-03-12
Recruiting
Incyte Corporation
Phase 3
600
Brussels, Ghent, Liège, Loverval, Woluwe-Saint-Lambert
2025-02-28
Recruiting
BioNTech SE
Phase 2/3
1,580
Ghent, Leuven, Mons, Roeselare, Sint-Niklaas, Woluwe-Saint-Lambert
2025-01-07
Recruiting
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06690775Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
DrugsTORL-1-23·Pegfilgrastim
TORL Biotherapeutics, LLC
Phase 2
230
Edegem, Woluwe-Saint-Lambert, Leuven, Liège
2024-11-20
Active, closed
Eli Lilly and Company
Phase 2
45
Ghent, Leuven, Woluwe-Saint-Lambert
2024-10-25
Active, closed
Incyte Corporation
Phase 3
346
Bruges, Ghent, Gilly, Liège, Woluwe-Saint-Lambert
2024-10-10
Active, closed
SynOx Therapeutics Limited
Phase 3
128
Woluwe-Saint-Lambert
2024-10-09
Recruiting
Lakefront Biotherapeutics NV
Phase 3
546
Edegem, Leuven, Liège, Roeselare, Woluwe-Saint-Lambert
2024-09-09
Recruiting
Eli Lilly and Company
Phase 3
510
Erpent, Ghent, Woluwe-Saint-Lambert
2024-04-29
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Bruges, Brussels, Ghent, Leuven, Liège, Overpelt, Woluwe-Saint-Lambert
2024-04-16
Active, closed
argenx
Observational
413
Brussels, Edegem, Ghent, Jette, Leuven, Liège, Woluwe-Saint-Lambert
2023-11-29
Active, closed
Incyte Corporation
Phase 3
467
Brussel/ Brussels/bruxelles, Ghent, Liège, Woluwe-Saint-Lambert
2023-11-29
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Edegem, Wilrijk, Woluwe-Saint-Lambert, Charleroi, Leuven
2023-11-16
Recruiting
Takeda
Phase 3
80
Brussels, Woluwe-Saint-Lambert, Ghent
2023-11-13
Recruiting
Université Catholique de Louvain
Observational
300
Woluwe-Saint-Lambert
2023-10-07
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Bonheiden, Ghent, Roeselare, Liège, Lodelinsart, Woluwe-Saint-Lambert
2023-07-06
Recruiting
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Not applicable
34
Woluwe-Saint-Lambert
2023-07-01
Active, closed
Servier Affaires Médicales
Phase 3
299
Brussels, Ghent, Leuven, Woluwe-Saint-Lambert
2023-05-03
Active, closed
Pfizer
Phase 3
624
Edegem, Woluwe-Saint-Lambert, Gilly, Leuven, Liège
2023-03-03
Active, closed
Klus Pharma Inc.
Phase 2
240
Brasschaat, Charleroi, Woluwe-Saint-Lambert
2023-01-17
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
297
Brussels, Edegem, Ghent, Leuven, Woluwe-Saint-Lambert
2022-11-23
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
822
Brussels, Ghent, Leuven, Woluwe-Saint-Lambert
2022-11-08
Active, closed
AZ Sint-Jan AV
Not applicable
170
Edegem, Lodelinsart, Hasselt, Liège, Ghent, Leuven, Woluwe-Saint-Lambert, Ottignies-Louvain-la-Neuve
2022-09-01
Recruiting
Stemline Therapeutics, Inc.
Phase 1/2
73
Edegem, Leuven, Woluwe-Saint-Lambert
2022-08-31
Recruiting
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
NCT04743765Hip Fractures, Myocardial Injury
Population Health Research Institute
Not applicable
1,100
Woluwe-Saint-Lambert
2021-11-22
Active, closed
Bioverativ, a Sanofi company
Phase 3
261
Woluwe-Saint-Lambert
2021-02-23
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Edegem, Leuven, Liège, Woluwe-Saint-Lambert
2021-02-01
Active, closed
argenx
Phase 2
229
Edegem, Leuven, Liège, Woluwe-Saint-Lambert
2020-09-18
Recruiting
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
NCT04263038Pulmonary Embolism, Embolism, Embolism and Thrombosis, Lung Diseases
DrugRivaroxaban
Drahomir Aujesky
Phase 4
276
Woluwe-Saint-Lambert, Liège
2020-05-15
Active, closed
AbbVie
Phase 1
85
Woluwe-Saint-Lambert
2019-11-08
Active, closed
AbbVie
Phase 3
1,533
Jette, Woluwe-Saint-Lambert, Ghent, Loverval
2018-08-09
Active, closed
Persona Partial Knee Clinical Outcomes Study
NCT03034811Osteoarthritis, Avascular Necrosis, Traumatic Arthritis, Conditional Tibial Condyle or Plateau Fractures
Zimmer Biomet
Not applicable
757
Woluwe-Saint-Lambert
2017-02-08
Active, closed
AbbVie
Phase 3
443
Jette, Woluwe-Saint-Lambert, Ghent, Bruges
2017-02-02
Active, closed
AbbVie
Phase 3
1,629
Woluwe-Saint-Lambert, Charleroi, Liège, Ghent, Mons
2015-12-01
Active, closed
Avenir® Cemented Hip Stem - PMCF
NCT03396224Primary Osteoarthritis, Post-Traumatic Osteoarthritis of Hip, Femoral Neck Fractures, Femoral Head Necrosis
Zimmer Biomet
Observational
100
Woluwe-Saint-Lambert
2015-11-18
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Brussels, Edegem, Ghent, Leuven, Liège, Woluwe-Saint-Lambert
2013-03-18
Rows per page Showing 1–57 of 57
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Belgian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 November 2026. https://priyalifescience.com/clinical-trials-belgium/city/woluwe-saint-lambert

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Belgium and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,055 studies in total at the last sync on 12 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 57 of those studies with a site in Woluwe-Saint-Lambert.

How many clinical trials are recruiting in Woluwe-Saint-Lambert?

33 of the 57 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 24 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Woluwe-Saint-Lambert), 57 studies
PhaseStudiesRecruitingShare
Phase 3301552.6%
Not applicable8514%
Phase 28514%
Observational427%
Phase 1213.5%
Phase 2/3223.5%
Phase 4223.5%
Phase 1/2111.8%

Most active sponsors

Lead sponsors with the most studies (Woluwe-Saint-Lambert)
Lead sponsorStudiesRecruiting
Incyte Corporation74
AbbVie40
Université Catholique de Louvain32
argenx20
BioNTech SE22
Cliniques universitaires Saint-Luc- Université Catholique de Louvain22
Eli Lilly and Company21
Janssen Research & Development, LLC22
Novartis Pharmaceuticals21
Olema Pharmaceuticals, Inc.21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.